Autolus Therapeutics Stock Analysis

Autolus Stock Analysis Notes

About 18.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.73. Some equities with similar Price to Book (P/B) outperform the market in the long run. Autolus Therapeutics recorded a loss per share of 0.88. The entity had not issued any dividends in recent years. Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. Autolus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 324 people. For more info on Autolus Therapeutics please contact Christian Itin at 44 20 3829 6230 or go to https://www.autolus.com.

Autolus Therapeutics Investment Alerts

Autolus Therapeutics Upcoming and Recent Events

Autolus Largest EPS Surprises

View All Earnings Estimates

Autolus Therapeutics Environmental, Social, and Governance (ESG) Scores

Autolus Stock Institutional Investors

Note, although Autolus Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Autolus Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 641.39 M.

Autolus Profitablity

Management Efficiency

Autolus Therapeutics has return on total asset (ROA) of (0.2028) % which means that it has lost $0.2028 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4997) %, meaning that it created substantial loss on money invested by shareholders. Autolus Therapeutics' management efficiency ratios could be used to measure how well Autolus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.3. The value of Return On Capital Employed is expected to slide to -0.35. At this time, Autolus Therapeutics' Fixed Asset Turnover is quite stable compared to the past year.

Technical Drivers

As of the 21st of July, Autolus Therapeutics shows the Mean Deviation of 3.78, risk adjusted performance of 0.2051, and Downside Deviation of 4.32. Autolus Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Autolus Therapeutics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Autolus Therapeutics is priced correctly, providing market reflects its regular price of 2.41 per share. Please also double-check Autolus Therapeutics total risk alpha, which is currently at 0.3276 to validate the company can sustain itself at a future point.

Autolus Therapeutics Price Movement Analysis

Autolus Therapeutics Outstanding Bonds

Autolus Therapeutics Predictive Daily Indicators

Autolus Therapeutics Forecast Models

Autolus Therapeutics' time-series forecasting models are one of many Autolus Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Autolus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Autolus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Autolus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Autolus Therapeutics. By using and applying Autolus Stock analysis, traders can create a robust methodology for identifying Autolus entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Autolus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Autolus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Autolus Therapeutics stock analysis indicators help investors evaluate how Autolus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Autolus Therapeutics shares will generate the highest return on investment. By understating and applying Autolus Therapeutics stock analysis, traders can identify Autolus Therapeutics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.